AbbVie Inc stock (US00287Y1091): FDA approval for rare blood cancer drug in focus as NYSE trading holds above USD 210

AbbVie stock on the NYSE remains firmly above USD 210 after the U.S. FDA cleared its targeted therapy Decnupaz for an ultra-rare blood cancer, keeping the large-cap U.S. pharma in the spotlight at the start of the week.

AbbVie Inc, the U.S.-based biopharmaceutical group listed on the NYSE under the ticker ABBV, starts the new week with investors still digesting a fresh U.S. regulatory milestone: the Food and Drug Administration has approved the company’s drug pivekimab sunirine-pvzy, marketed as Decnupaz, for adults with blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood and bone marrow cancer, according to an FDA communication on Wednesday in late May 2026 and subsequent market reports.

Market commentary noted that AbbVie shares gained on the day of the announcement as the approval highlighted the company’s push into highly targeted oncology treatments beyond its established immunology footprint, with the stock trading around USD 217 to USD 218 on the NYSE at the end of the week and remaining comfortably above USD 210, while year-to-date performance was reported at about a 6.4% decline from prior levels, according to recent coverage summarizing the move and price reaction.

The stock traded at USD 217.83 on the NYSE on Friday 05/29/2026, giving AbbVie a market capitalization of roughly USD 384.9 billion and placing it among the larger U.S. healthcare constituents followed by S&P 500 investors, according to pricing and market-cap data cited in a recent institutional holding update.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: AbbVie Inc
• Sector/industry: Biopharmaceuticals, immunology and oncology
• Headquarters/country: North Chicago, United States
• Core markets: United States, Europe, international pharmaceutical markets
• Key revenue drivers: Immunology therapies such as Humira and Skyrizi, oncology and hematologic oncology products, neuroscience and aesthetics portfolio
• Home exchange/listing venue: New York Stock Exchange (ABBV)
• Trading currency: USD

AbbVie Inc: core business model

AbbVie centers its business on discovering, developing and commercializing branded prescription medicines in immunology, oncology, neuroscience and aesthetics, with sales heavily influenced by the uptake and lifecycle of key therapies such as Humira, Skyrizi and Rinvoq alongside newer specialty drugs like Decnupaz in niche hematologic indications.

What banks and research houses say about AbbVie Inc

Analyst coverage of AbbVie remains active among major U.S. research houses because of the company’s large market capitalization and prominent role in immunology and oncology, although detailed, dated price-target changes tied directly to the Decnupaz approval over the past days have not yet been highlighted in publicly accessible bank notes at the time of writing.

Across consensus-based snapshots compiled by major data platforms in late May 2026, AbbVie continues to be tracked by a broad cohort of Wall Street analysts who typically focus on the durability of revenue from its immunology blockbusters Skyrizi and Rinvoq, the erosion profile of legacy product Humira and incremental contributions from its oncology pipeline, with the latest FDA approval for Decnupaz likely to be factored into upcoming models as an additional, albeit niche, revenue contributor rather than a transformational driver.

Conclusion

The latest FDA approval for Decnupaz adds another specialized oncology asset to AbbVie’s broad portfolio and comes as the New York-listed stock trades solidly above USD 210, reflecting the scale of its diversified revenue base.

While the rare blood cancer indication is unlikely to become a dominant revenue pillar in the near term, the decision underscores how AbbVie is seeking to balance established immunology cash flows with targeted innovations in oncology, an aspect that analysts are set to incorporate into their medium-term growth and risk assessments.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.